MRManee Rattanachaiyanont

Manee Rattanachaiyanont

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Manee Rattanachaiyanont has a total of 124 co-authors. Here are the top co-authors by number of shared publications:

  • Suchada Indhavivadhana

    Gynecologic Endocrinology Unit, Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

    24 shared publications
  • Pichai Leerasiri

    Gynecologic Endocrinology Unit Department of Obstetrics and Gynecology Faculty of Medicine Siriraj Hospital Mahidol University Bangkok Thailand

    13 shared publications
  • Kitirat Techatraisak

    Gynecologic Endocrinology Unit, Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

    12 shared publications
  • Surasak Angsuwathana

    Gynecologic Endocrinology Unit, Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

    11 shared publications
  • Thanyarat Wongwananuruk

    Gynecologic Endocrinology Unit, Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

    10 shared publications
  • Kitirat Techatraisak

    Gynecologic Endocrinology Unit, Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital Mahidol University Bangkok Thailand

    9 shared publications

Latest Publications

  • Open Access

    Gynecologic tumors in Thai women with breast cancer: a cross-sectional surveillance and ten-year cohort study

    by Preeyaporn Jirakittidul, Manee Rattanachaiyanont, Suchada Indhavivadhana, Chongdee Dangrat, Patsama Vichinsartvichai, Visnu Lohsiriwat

    Background: Breast cancer and gynecologic tumors share common hormonal and genetic risk factors. Previous studies mainly focused on the risk of endometrial pathology in women receiving tamoxifen, while the data on the overall prevalence of concurrent and subsequent gynecologic tumors in patients with breast cancer, especially in Asian populations, remain limited. Clarifying this association is important to survey the prevalence of concurrent gynecologic tumors and the incidence of de novo tumors in Thai women with breast cancer. This study aimed to determine the prevalence of concurrent gynecologic tumors and the incidence of de novo gynecologic tumors in Thai women with breast cancer. Methods: An initial cross-sectional study was conducted at the Faculty of Medicine Siriraj Hospital, Mahidol University. Participants were women scheduled for breast cancer surgery between September 2007 and January 2009. They were investigated for gynecologic tumors using clinical examination, cervical cytology testing, and pelvic ultrasonography; additional procedures were as indicated. In 2019, data from this cohort were reviewed for the de novo gynecologic tumors arising during the previous 10 years. Results: Concurrent gynecologic tumors were identified in 114 of 281 women (40.6%) with newly diagnosed breast cancer; most tumors were benign, including leiomyoma, adenomyosis, endometrial polyp, and ovarian tumor. Synchronous genital cancers were found in two cases, giving a prevalence of 0.7% [95% confidence interval (CI): 0.3–1.7]. During the 10-year follow-up period, de novo gynecologic tumors were found at an incidence of 3.1 per 100 person-years (95% CI: 2.1–4.4). Metachronous genital cancers were found in three cases, giving an incidence of 1.4 per 100 person-years (95% CI: 0.3–4.2). The risk of having either concurrent or de novo gynecologic tumors was associated with earlier age at menarche. Conclusions: Gynecologic tumors are prevalent in Thai women with breast cancer. The second primary genital cancers, both synchronous and metachronous, are not uncommon. Therefore, surveillance for the concurrent gynecologic tumors and further follow-up for the de novo ones should be considered in these patients.

  • Open Access

    Measures of Serum Markers HbA1c, HOMA-IR, HOMA-β, QUICKI and G/I Ratio as Predictors of Abnormal Glucose Tolerance Among Thai Women with Polycystic Ovary Syndrome

    by Thanyarat Wongwananuruk, Pichita Prasongvej, Panicha Chantrapanichkul, Suchada Indhavivadhana, Prasong Tanmahasamut, Manee Rattanachaiyanont, Kitirat Techatraisak, Surasak Angsuwathana

    Background/Objectives: Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder affecting women of reproductive age. It is associated with glucose intolerance, insulin resistance and diabetes mellitus. The oral glucose tolerance test (OGTT) is commonly employed to detect glucose intolerance, but it can be inconvenient and time-consuming. We aimed to evaluate the precision of haemoglobin A1c (HbA1c) and other serum markers in predicting abnormal glucose tolerance (AGT). Methods: This diagnostic study involved 121 PCOS women who attended the Gynaecologic Endocrinology Unit at Siriraj Hospital. Patients underwent assessments for weight, height, waist circumference, modified Ferriman–Gallwey score and acanthosis nigricans. Blood samples were collected to measure fasting glucose and insulin levels after a 75-gram oral OGTT, fasting insulin level, HbA1c, lipid profile, androgen profile and complete blood count. Homeostasis model assessment of insulin resistance (HOMA-IR), homeostasis model assessment of beta-cell function (HOMA-β), quantitative insulin sensitivity check index (QUICKI) and fasting glucose-to-insulin ratio (G/I ratio) were calculated. The sensitivity, specificity and accuracy of these serum markers were compared. Results: The prevalence of AGT was 24.8%. The area under the receiver operating characteristic curve for HbA1c in detecting AGT was 0.656, while HOMA-IR, HOMA-β, QUICKI and the G/I ratio had values of 0.817, 0.737, 0.817 and 0.77, respectively. The G/I ratio cut-off point of 6% demonstrated a sensitivity of 73.3%, specificity of 74.7%, positive predictive value of 48.9%, negative predictive value of 89.5% and accuracy of 74.4%. Conclusions: The G/I ratio is the most accurate compared to other serum markers in detecting AGT among Thai women with PCOS.


  • Open Access

    Associations Between BMI, Serum Hormone Levels, Time Since Ovarian Insufficiency Onset, Serologic Autoimmunity, and Prevalence of Common Parameters: A cross-sectional Retrospective Study of Premature Ovarian Insufficiency

    by Kitirat Techatraisak, Prasong Tanmahasamut, Suchada Indhavivadhana, Thanyarat Wongwananuruk, Manee Rattanachaiyanont, Chongdee Dangrat

    OBJECTIVE Premature ovarian insufficiency (POI) affects 1:100 women before the age of 40. The objectives include exploring correlations between body mass index, years since the onset of premature ovarian insufficiency, follicular stimulating hormone, and estradiol; and studying prevalence of five common serologic autoimmunologic para-meters during POI diagnosis.METHODS The records of idiopathic POI patients presenting with secondary amenorrhea who visited the Gynecologic Endocrinology Unit, Siriraj Hospital, between January 1, 2000 and December 31, 2016 were reviewed. Extracted data included body mass index, years since premature ovarian insufficiency onset, levels of follicular stimulating hormone and estradiol. Five common serologic autoimmunologic para-meters were also retrieved where available.RESULTS Among the 161 idiopathic POI patients analyzed, a signifi-cant reverse correlation was found between serum follicular stimulating hormone and estradiol (r=-0.209, p=0.008), while no correlations were identified between body mass index, years since the onset of pre-mature ovarian insufficiency, and serum estradiol (p=0.141, p=0.240, respectively). After excluding cases with abnormal karyotypes which can potentially cause POI, the remaining 146 cases was comprised of 72 cases with a normal 46,XX karyotype (the first group) and 74 cases who declined karyotype investigation (the second group). At least one of the serologic autoimmunologic parameters was investigated in 43 cases in the first group and in 20 cases in the second group. Anti-nuclear antibody was the most prevalent in the first group (25.0%) while anti-thyroglobulin was the most prevalent in the second group (30.7%).CONCLUSIONS Only serum follicular stimulating hormone and estra-diol exhibited significant reverse correlation in POI cases with secondary amenorrhea. Baseline serologic autoimmunologic parameters were positive but didn’t indicate autoimmune diseases during POI diagnosis.

  • Quality of life in Thai women with various types of abnormal uterine bleeding

    by Thanyarat Wongwananuruk, Manee Rattanachaiyanont, Chongdee Dangrat, Kitirat Techatraisak, Suchada Indhavivadhana, Prasong Tanmahasamut

    Objective: To determine the quality of life (QoL) in Thai women with various types of abnormal uterine bleeding (AUB). Methods: A cross‐sectional study was conducted on 353 AUB patients between November 2010 and January 2012. They were grouped according to the duration of symptom: n = 122), ≥6 months (chronic AUB, n = 138), and postmenopausal bleeding (PMB, n = 93); and the bleeding pattern: hypermenorrhea ( n = 24) and irregular bleeding ( n = 236). QoL was determined using the 36‐Item Short‐Form Health Survey (SF‐36) Thai version. Results: The acute AUB and chronic AUB groups had a mean age of 43.84 ± 4.87 and 43.81 ± 6.55 years; they were younger than the PMB group (55.62 ± 7.55 years) ( P < 0.001). Medical diseases were more prevalent in the PMB than in the acute and chronic groups (66.7% vs. 27.9% and 35.5%, respectively, P < 0.001). Some subscales of the SF‐36 were significantly lower in the women with AUB than in those with normative values, in those with chronic AUB or PMB than in those with acute AUB, and in those with hypermenorrhea rather than in those with irregular bleeding. Conclusion: Thai women with any AUB types have a poorer QoL than general Thai women. QoL tends to be poorer in women with symptoms longer than 6 months or with hypermenorrhea.


  • Open Access

    The effectiveness of desogestrel for endometrial protection in women with abnormal uterine bleeding-ovulatory dysfunction: a non-inferiority randomized controlled trial

    by Nisarath Soontrapa, Manee Rattanachaiyanont, Malee Warnnissorn, Thanyarat Wongwananuruk, Suchada Indhavivadhana, Prasong Tanmahasamut, Kitirat Techatraisak, Surasak Angsuwathana

    Women with chronic abnormal uterine bleeding-ovulatory dysfunction (AUB-O) are at increased risk of endometrial neoplasia. We conducted a non-inferiority randomized controlled trial to determine the effectiveness of two cyclic-progestin regimens orally administered 10 d/month for 6 months on endometrial protection and menstruation normalization in women with AUB-O. There were 104 premenopausal women with AUB-O randomized to desogestrel (DSG 150 µg/d, n = 50) or medroxyprogesterone acetate (MPA 10 mg/d, n = 54) group. Both groups were comparable in age (44.8 ± 5.7 vs. 42.5 ± 7.1 years), body mass index (24.8 ± 4.7 vs. 24.9 ± 4.7 kg/m2), and AUB characteristics (100% irregular periods). The primary outcome was endometrial response rate (the proportion of patients having complete pseudodecidualization in endometrial biopsies during treatment cycle-1). The secondary outcome was clinical response rate (the proportion of progestin withdrawal bleeding episodes with acceptable bleeding characteristics during treatment cycle-2 to cycle-6). DSG was not inferior to MPA regarding the endometrial protection (endometrial response rate of 78.0% vs. 70.4%, 95% CI of difference − 9.1–24.4%, non-inferiority limit of − 10%), but it was less effective regarding the menstruation normalization (acceptable bleeding rate of 90.0% vs 96.6%, P = 0.016). Clinical trial registration: ClinicalTrials.gov (NCT02103764, date of approval 18 Feb 2014).


  • Menopausal hormonal therapy in surgically menopausal women with underlying endometriosis

    by P. Tanmahasamut, M. Rattanachaiyanont, K. Techatraisak, S. Indhavivadhana, T. Wongwananuruk, P. Chantrapanichkul

    This study aimed to investigate the relationship between menopausal hormone therapy (MHT) and endometriosis recurrence in women who underwent hysterectomy with bilateral salpingo-oophorectomy to tr...


  • Impact of Global Consensus Statement on compliance with hormonal therapy for surgical menopause

    by K. Techatraisak, M. Rattanachaiyanont, P. Tanmahasamut, S. Indhavivadhana, T. Wongwananuruk, P. Jirakittidul

    Initiation of and compliance with menopausal hormonal therapy (MHT) have been dropping due to the 2002 Women’s Health Initiative (WHI) publication. We evaluated the change in practice of MHT for surgical menopause after implementing the 2013 ‘Global Consensus Statement on MHT’ to our institutional guideline. A retrospective study was conducted in surgically menopausal women newly registering at the Siriraj Menopause Clinic in a university hospital, Thailand, from 1995 to 2013. The patients were categorized into four groups according to periods of MHT initiation: 1995–1998 (control), 2000–2003 (WHI affected), 2005–2008 (post WHI) and 2010–2013 (Global Consensus Statement affected). Their 3-year compliance with MHT was compared using forward stepwise regression analysis. There were 288, 156, 107 and 104 cases in the 1995–1998, 2000–2003, 2005–2008 and 2010–2013 groups. Their mean age at surgery was 42.8 ± 4.7 years. After the first, second and third years, overall compliance was 82.4%, 70.9% and 61.2%, respectively. The 3-year compliance drastically dropped in the 2000–2003 group, and then improved to control level in the 2010–2013 group (51.9% vs. 77.9%, p = 0.035). The initiation of MHT continuously dropped during 2000–2013; however, compliance with MHT initiated during 2010–2013 improved after implementing the 2013 ‘Global Consensus Statement on MHT’ to our institutional guideline. Each institute should have a strategy to encourage the initiation of and compliance with MHT for surgical menopause to achieve long-term health benefits.

  • Effectiveness of vitamin D2 supplementation on high-sensitivity C-reactive protein and other metabolic indices in menopausal Thai women: a randomized-controlled trial

    by Suchada Indhavivadhana, Worawat Boonyachan, Manee Rattanachaiyanont, Thanyarat Wongwananuruk, Kitirat Techatraisak, Nutchaya Sa-Nga-Areekul

    Vitamin D2 supplementation in menopausal Thai women can reduce hsCRP level and might be superior to placebo.


  • Open Access

    Polycystic ovarian morphology in Thai women of reproductive age with polycystic ovary syndrome

    by Thanyarat Wongwananuruk, Panicha Chantrapanichkul, Vichuta Unalome, Suchada Indhavivadhana, Manee Rattanachaiyanont, Kitirat Techatraisak, Surasak Angsuwathana, Kittayaporn Silprasit

    Background: Advancements in ultrasound technology have facilitated identifying polycystic ovarian morphology (PCOM) in women with and without polycystic ovary syndrome (PCOS), but it still has limitations due to follicle counting methods and variation of phenotypes according to ethnicity. Ethnicity-specific ovarian morphology may help to establish ethnicity-specific follicle count cut points for defining PCOM in women with PCOS. Objectives: To investigate the prevalence and factors associated with PCOM in Thai women of a reproductive age with PCOS. Methods: This prospective cross-sectional study was conducted in our gynecology department at a tertiary teaching hospital from February 2016 to May 2017. We included women with PCOS, who were measured for weight, height, waist circumference, and blood pressure. Blood samples were taken to measure fasting blood glucose, lipid profile, testosterone level, and 2 h post-load 75 g oral glucose tolerance test (OGTT). Transvaginal or transrectal sonography was performed to evaluate their ovaries. Results: All 143 patient participants we included had oligomenorrhea, 77.6% of them had acne, and 64.3% hirsutism. Their average total testosterone level was 0.47 ± 0.10 ng/mL. The prevalence of PCOM was 55.2%. The proportions of PCOM diagnosed by ovarian follicle and ovarian volume criteria were 36.4% and 42.0%, respectively. There were 20.0 ± 9.5 follicles per ovary, 8.3 ± 3.1 follicles per cross section, and the mean ovarian volume was 7.9 ± 3.0 mL. Conclusion: The overall prevalence of PCOM in Thai women of reproductive age with PCOS was 55.2%. Our univariate analysis found no factors significantly associated with PCOM.


  • Open Access

    The effectiveness of quick starting oral contraception containing nomegestrol acetate and 17-β estradiol on ovulation inhibition: A randomized controlled trial

    by Preeyaporn Jirakittidul, Surasak Angsuwathana, Manee Rattanachaiyanont, Thunyada Thiampong, Chanon Neungton, Benjaphorn Chotrungrote

    To determine the effectiveness of quick starting combined oral contraception (COC) contain 2.5 mg nomegestrol acetate and 1.5 mg estradiol (NOMAC/E2) comparing with 0.075 mg gestodene and 0.02 mg ethinyl estradiol (GS/EE) on ovarian ovulation inhibition rate, we conducted a non-inferiority randomized controlled trial involving 69 healthy female volunteers aged 18–40 years who had normal menstrual history and were randomized at a 2:1 ratio to take one pack of COC containing either NOMAC/E2 (study group) or GS/EE (control group) starting on menstrual cycle Day7–9. The ovarian activity was assessed by using Hoogland and Skouby grading. Forty-six and 23 participants were randomized to NOMAC/E2 and GS/EE groups, respectively. Baseline characteristics were similar between groups. No significant difference was observed between the study and control groups for ovulation inhibition rate (93.4% vs. 95.6%, risk difference: –2.2%, 95% CI: –13.1, 8.8), ovarian quiescence rate (91.2% vs. 91.2%, P = 1.000), persistent cyst rate (2.2% vs. 4.4%, P = 1.000), and ovulation rate (6.6% vs. 4.4%, P = 1.000). Quick starting COC during day7–9 of menstrual cycle can inhibit ovulation for more than 90%. The quick starting NOMAC/E2 is non-inferior to GS/EE for preventing ovulation and suppressing follicular growth.